CHIARADONNA, FERDINANDO
CHIARADONNA, FERDINANDO
DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE
ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis
In corso di stampa De, V; Battaglia, A; Pallocca, M; Santamaria, G; Mimmi, M; Sacco, A; De Nicola, F; Gaspari, M; Salvati, V; Ascenzi, F; Bruschini, S; Esposito, A; Ricci, G; Sperandio, E; Prestagiacomo, L; Cavaliere, R; Vecchione, A; Ricci, A; Sciacchitano, S; Salerno, G; French, D; Aversa, I; Cereda, C; Fanciulli, M; Chiaradonna, F; Cuda, G; Costanzo, F; Ciliberto, G; Mancini, R; Biamonte, F
Hexosamine Biosynthetic Pathway inhibition sensitizes pancreatic cancer cells to DNA damage
2025 Zerbato, B; Brancato, V; Giampà, M; Taverna, G; Monterosso, G; Taglietti, L; Lombardi, S; Fontana, C; La Chimia, M; Barabino, S; Urbanucci, A; La Ferla, B; Scumaci, D; Chiaradonna, F
Hexosamine Pathway inhibition: one molecule able to induce a Brcaness phenotype as promising cancer therapy
2025 Zerbato, B; Brancato, V; Giampà, M; Taverna, G; Monterosso, G; Taglietti, L; Lombardi, S; Fontana, C; La Chimia, M; Barabino, S; La Ferla, B; Scumaci, D; Chiaradonna, F
Inhibition of the Hexosamine Biosynthetic Pathway Enhances Enzalutamide Response in Prostate Cancer Cells
2025 Zerbato, B; Cecchetto, T; Sajnani, K; Chiaradonna, F; Urbanucci, A
Multi-pathway blood biomarkers to target and monitor multidimensional prevention of cognitive and functional decline (nested in the IN-TeMPO study framed within the world-wide FINGERS network)
2025 Sala, G; Cuffaro, L; Pozzi, F; Andreoni, S; Bazzini, C; Conti, E; Zoia, C; Beretta, S; Tremolizzo, L; Bellelli, G; Okoye, C; Ferrara, M; De Luca, A; Lenti, R; Mantuano, P; Pontrelli, P; Stasi, A; Defazio, G; Solfrizzi, V; Crudele, L; Airoldi, C; Chiaradonna, F; Longhese, M; Messina, G; Natalello, A; Orlandi, I; Aloisi, A; Capone, S; Ingannato, A; Nacmias, B; Capello, D; Mangialasche, F; Ferrarese, C
PGM3 Inhibition as a Novel Strategy to Induce BRCAness in HR-Proficient Pancreatic Cancer Cells
2025 Zerbato, B; Brancato, V; Giampà, M; Taverna, G; Monterosso, G; Taglietti, L; Lombardi, S; Fontana, C; La Chimia, M; Barabino, S; La Ferla, B; Scumaci, D; Chiaradonna, F
PGM3 Inhibition as a Novel Strategy to Induce BRCAness in HR-Proficient Pancreatic Cancer Cells
2025 Zerbato, B; Brancato, V; Giampà, M; Taverna, G; Monterosso, G; Taglietti, L; Lombardi, S; Fontana, C; La Chimia, M; Barabino, S; La Ferla, B; Scumaci, D; Chiaradonna, F
PGM3 insufficiency: a glycosylation disorder causing a notable T cell defect
2025 Yang, L; Zerbato, B; Pessina, A; Brambilla, L; Andreani, V; Frey-Jakobs, S; Fliegauf, M; Barbouche, M; Zhang, Q; Chiaradonna, F; Proietti, M; Du, X; Grimbacher, B
Chiral trimethyl lock based on vicinal disubstituent effect: prolonged release of Camptothecin into cancer cells
2024 Venturi, S; Chiaradonna, F; Gatti, F; La Ferla, B; Parolini, R; Zerbato, B
Hexosamine Biosynthetic Pathway inhibition cooperates with gemcitabine inducing in vitro and in vivo pancreatic cancer regression by enhancing DNA damage
2024 Zerbato, B; Brancato, V; La Chimia, M; Gobbi, M; Lattuada, C; Pessina, A; Brambilla, L; Wegner, A; Scumaci, D; Chiaradonna, F
Hexosamine biosynthetic pathway inhibition cooperates with gemcitabine inducing in vitro and in vivo pancreatic cancer regression by enhancing DNA damage
2024 Zerbato, B; Brancato, V; Lattuada, C; La Chimia, M; Scumaci, D; Chiaradonna, F
PGM3 inhibition shows cooperative effects with Erastin inducing pancreatic cancer cell death via activation of the Unfolded Protein Response
2024 Zerbato, B; Gobbi, M; Ludwig, T; Brancato, V; Pessina, A; Brambilla, L; Wegner, A; Chiaradonna, F
PGM3 insufficiency: a glycosylation disorder causing a notable T cell defect
2024 Yang, L; Zerbato, B; Pessina, A; Brambilla, L; Andreani, V; Frey-Jakobs, S; Fliegauf, M; Barbouche, M; Zhang, Q; Chiaradonna, F; Proietti, M; Du, X; Grimbacher, B
Targeting Hexosamine Biosynthetic Pathway to Overcome Resistance in Pancreatic Cancer Treatment
2024 Zerbato, B; Brancato, V; Gobbi, M; Lattuada, C; La Chimia, M; Pessina, A; Brambilla, L; Wegner, A; Scumaci, D; Chiaradonna, F
Targeting Hexosamine Biosynthetic Pathway to Overcome Resistance in Pancreatic Cancer Treatment
2024 Zerbato, B; Brancato, V; Gobbi, M; Lattuada, C; La Chimia, M; Pessina, A; Brambilla, L; Wegner, A; Scumaci, D; Chiaradonna, F
Targeting the Hexosamine Biosynthetic Pathway with a novel PGM3 inhibitor, FR054, to suppress tumour growth and enhance chemotherapy sensitivity in cancer
2024 Zerbato, B; Brancato, V; Gobbi, M; Lattuada, C; La Chimia, M; Pessina, A; Brambilla, L; Wegner, A; Scumaci, D; Chiaradonna, F
Targeting the Unfolded Protein Response for Breast and Pancreatic Cancer Therapy
2024 Zerbato, B; Brancato, V; Gobbi, M; Pessina, A; Brambilla, L; Wegner, A; Chiaradonna, F
Targeting the Unfolded Protein Response for Breast and Pancreatic Cancer Therapy
2024 Zerbato, B; Brancato, V; Gobbi, M; Pessina, A; Brambilla, L; Wegner, A; Chiaradonna, F
Targeting the Unfolded Protein Response for Breast and Pancreatic Cancer Therapy
2024 Zerbato, B; Brancato, V; Gobbi, M; Pessina, A; Brambilla, L; Wegner, A; Chiaradonna, F
ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis
2023 De Vitis, C; Battaglia, A; Pallocca, M; Santamaria, G; Mimmi, M; Sacco, A; De Nicola, F; Gaspari, M; Salvati, V; Ascenzi, F; Bruschini, S; Esposito, A; Ricci, G; Sperandio, E; Massacci, A; Prestagiacomo, L; Vecchione, A; Ricci, A; Sciacchitano, S; Salerno, G; French, D; Aversa, I; Cereda, C; Fanciulli, M; Chiaradonna, F; Solito, E; Cuda, G; Costanzo, F; Ciliberto, G; Mancini, R; Biamonte, F